NM  Vol.2 No.2 , June 2011
Advances in Oligoprotection
Abstract: Oligodendrocytes, the myelinating glial cells of the nervous system, in various disease states display great vulnerability to excitotoxic damage, oxidative stress, and inflammatory cytokines. Besides demyelinating diseases where oligoden-drocyte injury is primarily implicated, damage to them also occurs secondarily in various neuropathies. Oligoprotec-tion should, therefore, be looked into something not just as a means for protecting oligodendrocytes alone but also as a common target of protecting neurons and the neurogliovascular unit as a whole. In this review, we provide a descrip-tion on oligodendrocytes, the reasons for their vulnerability, the evolving new concepts of protecting neurovascular unit and recently neurogliovascular unit; the various diseases where oligodendrocyte injury is implicated with a brief idea on different injury mechanisms of oligodendrocytes. Finally, we present the summary of the drugs that have shown promising results in protecting oligodendrocytes or in protecting white matter as a whole in different in-vivo and in-vitro models.
Cite this paper: nullH. Liao and D. Mani, "Advances in Oligoprotection," Neuroscience and Medicine, Vol. 2 No. 2, 2011, pp. 93-103. doi: 10.4236/nm.2011.22014.

[1]   K. Arai and E.H. Lo, “Oligovascular Signaling in White Matter Stroke,” Biological & Pharmaceutical Bulletin, Vol. 32, No. 10, 2009, pp. 1639-1644.

[2]   M. Bastide, T. Ouk, F. Plaisier, O. Pétrault, S. Stolc, and R. Bordet, “Neurogliovascular unit after cerebral ischemia: is the vascular wall a pharmacological target,” Psychoneuro-endocrinology, Vol. 32 Suppl 1, No. 1, 2007, pp. S36-39.

[3]   B.V. Zlokovic, “Neurodegeneration and the neurovascular unit,” Nature Medicine, Vol. 16, No.12, 2010, pp. 1370-1371.

[4]   N. Baumann and D. Pham-Dinh, “Biology of Oligoden-drocyte and Myelin in the Mammalian Central Nervous System,” Physiological Reviews, Vol. 81, No. 2, 2001, pp. 871-927.

[5]   G. Bartzokis, “Age-related myelin breakdown: a develop-mental model of cognitive decline and Alzheimer’ s dis-ease,” Neurobiology of Aging, Vol. 25, No. 1, 2004, pp. 5-18.

[6]   J. van Horssen, M.E. Witte, G. Schreibelt, and H.E. de Vries, “Radical changes in multiple sclerosis pathogene- sis,” Biochimica et Biophysica Acta, Vol. 1812, No. 2, 2010, pp. 141-150.

[7]   M. Bradl and H. Lassmann, “Oligodendrocytes: biology and pathology,” Acta Neuropathologica, Vol. 119, No. 1, 2010, pp. 37-53.

[8]   C. Richter-Landsberg and U. Vollgraf, “Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells,” Experimental Cell Re- search, Vol. 244, No. 1, 1998, pp. 218-229.

[9]   M. Nedergaard, J.J. Rodríguez, and A. Verkhratsky, “Glial calcium and diseases of the nervous system,” Cell Calcium, Vol. 47, No. 2, 2010, pp. 140-149.

[10]   David Zieve, “Multiple sclerosis,” Pubmed Health, 2010.

[11]   C.A. Tegla, C. Cudrici, V. Rus, T. Ito, S. Vlaicu, A. Singh, and H. Rus, “Neuroprotective effects of the com-plement terminal pathway during demyelination: implica-tions for oligodendrocyte survival,” Journal of Neuro-immunology, Vol. 213, No. 1-2, 2009, pp. 3-11.

[12]   A. Jana and K. Pahan, “Oxidative Stress Kills Human Primary Oligodendrocytes Via Neutral Sphingomyelinase: Implications for Multiple Sclerosis,” Journal of Neuro- immune Pharmacology, Vol. 2, No. 1, 2007, pp. 184-193.

[13]   M. Vanmeeteren, J. Hendriks, C. Dijkstra, and E. Vantol, “Dietary compounds prevent oxidative damage and nitric oxide production by cells involved in demyelinating dis- ease,” Biochemical Pharmacology, Vol. 67, No. 5, 2004, pp. 967-975.

[14]   C. Matute, E. Alberdi, M. Domercq, M.-V. Sán-chez- Gómez, A. Pérez-Samartín, A. Rodríguez-Antigüedad, and F. Pérez-Cerdá, “Excitotoxic damage to white matter,” Journal of Anatomy, Vol. 210, No. 6, 2007, pp. 693-702.

[15]   Y. Zhang, C. Taveggia, C. Melendez-Vasquez, S. Ein- heber, C.S. Raine, J.L. Salzer, C.F. Brosnan, and G.R. John, “Interleukin-11 potentiates oligodendrocyte sur- vival and maturation, and myelin formation,” The Jour- nal of Neuroscience, Vol. 26, No. 47, 2006, pp. 12174- 12185.

[16]   S. A Back, N.L. Luo, N.S. Borenstein, J.M. Levine, J.J. Volpe, and H.C. Kinney, “Late oligodendrocyte progeni-tors coincide with the developmental window of vulner-ability for human perinatal white matter injury,” The Journal of Neuroscience, Vol. 21, No. 4, 2001, pp. 1302-12.

[17]   M.V. Johnston, A. Ishida, W.N. Ishida, H.B. Matsushita, A. Nishimura, and M. Tsuji, “Plasticity and injury in the developing brain,” Brain & Development, Vol. 31, No. 1, 2009, pp. 1-10.

[18]   Y. Pang, L. Campbell, B. Zheng, L. Fan, Z. Cai, and P. Rhodes, “Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development,” Neuroscience, Vol. 166, No. 2, 2010, pp. 464-475.

[19]   K.G. Lee, “Periventricular leukomalacia,” Pubmed Health, 2009.

[20]   J.J. Volpe, H.C. Kinney, E.J. Frances, and P.A. Rosen- berg (In press), “The developing oligodendrocyte: key cellular target in brain injury in the premature infant,” International Journal of Developmental Neuroscience.

[21]   D.B. Hoch, “Stroke,” Pubmed Health, 2010.

[22]   [22] A.S. Hazell, “Excitotoxic mechanisms in stroke: an up-date of concepts and treatment strategies,” Neurochemis-try International, Vol. 50, No. 7-8, 2007, pp. 941-953.

[23]   W. Pan and A.J. Kastin, “Tumor necrosis factor and stroke: role of the blood-brain barrier,” Progress in Neu-robiology, Vol. 83, No. 6, 2007, pp. 363-374.

[24]   D. Dewar, S.M. Underhill, and M.P. Goldberg, “Oli- godendrocytes and Ischemic Brain Injury,” Journal of Cerebral Blood Flow & Metabolism, Vol. 23, No. 1, 2003, pp. 263-274.

[25]   E.H. Lo, T. Dalkara, and M. a Moskowitz, “Mechanisms, challenges and opportunities in stroke,” Nature Reviews. Neuroscience, Vol. 4, No. 5, 2003, pp. 399-415.

[26]   D. Zieve, “Spinal cord trauma,” Pubmed Health, 2010.

[27]   R. Talac, J.A. Friedman, M.J. Moore, L. Lu, E. Jabbari, A.J. Windebank, B.L. Currier, and M.J. Yaszemski, “Animal models of spinal cord injury for evaluation of tissue engineering treatment strategies,” Biomaterials, Vol. 25, No. 9, 2004, pp. 1505-1510.

[28]   G.D. Carlson and C. Gorden, “Current developments in spinal cord injury research,” The Spine Journal, Vol. 2, No. 1, 2002, pp. 116-128.

[29]   Y.H. Ahn, G. Lee, and S.K. Kang, “Molecular insights of the injured lesions of rat spinal cords: Inflammation, apoptosis, and cell survival,” Biochemical and Biophysi-cal Research Communications, Vol. 348, No. 1, 2006, pp. 560-570.

[30]   “Leukodystrophies,” Medline Plus, 2011.

[31]   R. Káradóttir and D. Attwell, “Neurotransmitter recep- tors in the life and death of oligodendrocytes,” Neurosci-ence, Vol. 145, No 4-5, 2007, pp. 1426 -1438.

[32]   B.D. Butts, C. Houde, and H. Mehmet, “Matura-tion- dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease,” Cell Death and Differentiation, Vol. 15, No. 1, 2008, pp. 1178-1186.

[33]   A.D. Roth, G. Ramírez, and R. Alarcón, R.V. Bernhardi, “Oligodendrocytes damage in Alzheimer’ s disease : Beta amyloid toxicity and inflammation,” Biological Re-search, Vol. 38, No. 1, 2005, pp. 381-387.

[34]   David B. Merrill, “Schizophrenia,” Pubmed Health, 2010.

[35]   N.A. Uranova, V.M. Vostrikov, O.V. Vikhreva, I.S. Zi-mina, N.S. Kolomeets, and D.D. Orlovskaya, “The role of oligodendrocyte pathology in schizophrenia.,” The In-ternational Journal of Neuropsychopharmacology, Vol. 10, No. 4, 2007, pp. 537-545.

[36]   P.R. Hof, V. Haroutunian, C. Copland, K.L. Davis, and J.D. Buxbaum, “Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia,” Neuro- chemical Research, Vol. 27, No. 10, 2002, pp. 1193- 1200.

[37]   D. Segal, J.R. Koschnick, L.H.A. Slegers, and P.R. Hof, “Oligodendrocyte pathophysiology: a new view of schi- zophrenia.,” The International Journal of Neuropsycho- pharmacology, Vol. 10, No. 4, 2007, pp. 503-511.

[38]   A. Verkhratsky and V. Parpura, “Recent advances in (pa-tho)physiology of astroglia.,” Acta Pharmacologica Si-nica, Vol. 31, No. 1, 2010, pp. 1044-1054.

[39]   C. Mihai and B. Jubelt, “Post-infectious encephalomye- litis,” Current Neurology and Neuroscience Reports, Vol. 5, No. 1, 2005, pp. 440-445.

[40]   K. Sano, K. Morii, M. Sato, H. Mori, and R. Tanaka, “Radiation-induced diffuse brain injury in the neonatal rat model--radiation-induced apoptosis of oligodendro- cytes,” Neurologia Medico-Chirurgica, Vol. 40, No. 10, 2000, pp. 495-499.

[41]   A. Ernst, A. Stolzing, G. Sandig, and T. Grune, “Anti-oxidants effectively prevent oxidation-induced protein damage in OLN 93 cells,” Archives of Biochemistry and Biophysics, Vol. 421, No. 1, 2004, pp. 54-60.

[42]   [42] H. Mann, M.T. McCoy, J. Subramaniam, H.V. Remmen, and J.L. Cadet, “Overexpression of superoxide dismutase and catalase in immortalized neural cells: toxic effects of hydrogen peroxide,” Brain Research, Vol. 770, No. 1, 1997, pp. 163-168.

[43]   C. Matute, “Oligodendrocyte NMDA receptors: a novel therapeutic target,” Trends in Molecular Medicine, Vol. 12, No. 7, 2006, pp. 289-292.

[44]   E.A. Leuchtmann, A.E. Ratner, R. Vijitruth, Y. Qu, and J.W. Mcdonald, “AMPA receptors are the major media-tors of excitotoxic death in mature oligodendrocytes,” Neurobiology of Disease, Vol. 14, No. 1, 2003, pp. 336- 348.

[45]   W. Cammer and H. Zhang, “Maturation of oligodendro- cytes is more sensitive to TNF-a than is survival of pre- cursors and immature oligodendrocytes,” Journal of Neuroimmunology, Vol. 97, No. 1, 1999, pp. 37-42.

[46]   W. Chadwick, T. Magnus, B. Martin, A. Keselman, M.P. Mattson, and S. Maudsley, “Targeting TNF-α receptors for neurotherapeutics,” Trends in Neurosciences, Vol. 31, No. 10, 2008, pp. 504-511.

[47]   W. Cammer, “Protection of cultured oligodendrocytes against tumor necrosis factor-alpha by the antioxidants coenzyme Q(10) and N-acetyl cysteine,” Brain Research Bulletin, Vol. 58, No. 6, 2002, pp. 587-592.

[48]   J.L. Takahashi, F. Giuliani, C. Power, Y. Imai, and V.W. Yong, “Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity,” Annals of Neurology, Vol. 53, No. 5, 2003, pp. 588-595.

[49]   T.Y. Yune, J.Y. Lee, G.Y. Jung, S.J. Kim, M.H. Jiang, Y.C. Kim, Y.J. Oh, G.J. Markelonis, and T.H. Oh, “Mi-nocycline alleviates death of oligodendrocytes by inhib-iting pro-nerve growth factor production in microglia af-ter spinal cord injury,” The Journal of Neuroscience, Vol. 27, No. 29, 2007, pp. 7751-7761.

[50]   H. Li, G. Klein, P. Sun, and a M. Buchan, “CoQ10 fails to protect brain against focal and global ischemia in rats,” Brain Research, Vol. 877, No. 1, 2000, pp. 7-11.

[51]   Y. Nakamura, Q. Feng, T. Kumagai, K. Torikai, H. Ohi-gashi, T. Osawa, N. Noguchi, E. Niki, and K. Uchida, “Ebselen , a Glutathione Peroxidase Mimetic Se-leno- organic Compound , as a Multifunctional Antioxi-dant,” The Journal of Biological Chemistry, Vol. 277, No. 4, 2002, pp. 2687-2694

[52]   Y. Ueno, N. Zhang, N. Miyamoto, R. Tanaka, N. Hattori, and T. Urabe, “Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfu-sion model,” Neuroscience, Vol. 162, No. 2, 2009, pp. 317-327.

[53]   J.-M. Lee, P. Yan, Q. Xiao, S. Chen, K.-Y. Lee, C.Y. Hsu, and J. Xu, “Methylprednisolone protects oligodendro- cytes but not neurons after spinal cord injury,” The Jour- nal of Neuroscience, Vol. 28, No. 12, 2008, pp. 3141- 3149.

[54]   J.C. Louis, E. Magal, S. Takayama, and S. Varon, “CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death,” Science, Vol. 259, No. 5095, 1993, pp. 689-692

[55]   D.D. Rowe, C.C. Leonardo, A.A. Hall, M.D. Shahaduz-zaman, L.A. Collier, A.E. Willing, and K.R. Pennypacker, “Cord blood administration induces oligodendrocyte sur-vival through alterations in gene expression,” Brain Re-search, Vol. 1366, No. 1, 2010, pp. 172-188.

[56]   S. Genc, K. Genc, A. Kumral, and H. Ozkan, “White matter protection by erythropoietin: an emerging matter in the treatment of neonatal hypoxic-ischemic brain in-jury,” Stroke, Vol. 41, No. 11, 2010, p. e595.

[57]   C. Cid and A. Alcazar, “Protection of oligodendrocyte precursor cells by low doses of HSP90 inhibitors in cell culture,” Experimental Neurology, Vol. 225, No. 7, 2010, pp. 29-33.

[58]   B.G. Xiao, X.F. Bail, G.X. Zhang, G. Hedlund, and H. Link, “Linomide-mediated protection of oligodendro- cytes is associated with inhibition of nitric oxide produc- tion and IL-1beta expression in Lewis rat glial cells,” Neuroscience Letters, Vol. 249, No. 1, 1998, pp. 17-20.

[59]   E.-J. Lee, M.-Y. Lee, H.-Y. Chen, Y.-S. Hsu, T.-S. Wu, S.-T. Chen, and G.-L. Chang, “Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia,” Journal of Pineal Research, Vol. 38, No. 1, 2005, pp. 42-52.

[60]   K. Arai and E.H. Lo, “Experimental models for analysis of oligodendrocyte pathophysiology in stroke,” Experi- mental & Translational Stroke Medicine, Vol. 1, No. 6, 2009.

[61]   R. Takano, S. Hisahara, K. Namikawa, H. Kiyama, H. Okano, and M. Miura, “Nerve growth factor protects oli-godendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms,” The Journal of Biological Chemistry, Vol. 275, No. 21, 2000, pp. 16360-16365.

[62]   J.-S. Kim, I. Yun, Y.B. Choi, K.-S. Lee, and Y.-I. Kim, “Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat,” Journal of Clinical Neuroscience, Vol. 15, No. 2, 2008, pp. 174-178.

[63]   R. Fern, B.R. Ransom, P.K. Stys, and S.G. Waxman, “Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diaze-pam,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 266, No. 3, 1993, pp. 1549-1555.

[64]   W.H. Lagarde, R. Benjamin, A.T. Heerens, P. Ye, R.I. Cohen, B.M. Moats-staats, and A.J. D’ercole, “A non- transformed oligodendrocyte precursor cell line, OL-1, facilitates studies of insulin-like growth factor-I signaling during oligodendrocyte development,” Interna-tional Journal of Developmental Neuroscience, Vol. 25, No. 2, 2007, pp. 95-105.

[65]   A. Musarò, G. Dobrowolny, and N. Rosenthal, “The neuroprotective effects of a locally acting IGF-1 iso-form.,” Experimental Gerontology, Vol. 42, No. 1-2, 2007, pp. 76-80.

[66]   P. Ye and A.J. D?Ercole, “Insulin-like growth factor I protects oligodendrocytes from tumor necrosis fac-tor-alpha-induced injury,” Endocrinology, Vol. 140, No. 7, 1999, pp. 3063-3072.

[67]   F.A. McMorris, T.M. Smith, S. DeSalvo, and R.W. Fur- lanetto, “Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development,” Pro- ceedings of the National Academy of Sciences of the United States of America, Vol. 83, No. 3, 1986, pp. 822-826.

[68]   J.L. Mason, S. Xuan, I. Dragatsis, A. Efstratiadis, and J.E. Goldman, “Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination,” The Journal of Neuroscience, Vol. 23, No. 20, 2003, pp. 7710-7718.

[69]   S.A. Jones, D.M. Jolson, K.K. Cuta, C.N. Mariash, and G.W. Anderson, “Triiodothyronine is a survival factor for developing oligodendrocytes,” Molecular and Cellular Endocrinology, Vol. 199, No. 1-2, 2003, pp. 49-60.

[70]   M. Sugawa, Y. Sakurai, Y. Ishikawa-ieda, H. Suzuki, and H. Asou, “Effects of erythropoietin on glial cell devel-opment; oligodendrocyte maturation and astrocyte prolif-eration,” Neuroscience Research, Vol. 44, No. 4, 2002, pp. 391-403.

[71]   P.K. Stys, “White matter injury mechanisms,” Current Molecular Medicine, Vol. 4, No. 2, 2004, pp. 113-130.